Analisis Efektivitas Biaya Penggunaan Pioglitazone Dibandingkan Glimepiride Pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit Wilayah Kota Mataram

Kholida Zhahara, Diesty Anita Nugraheni, Okti Ratna Mafruhah

Abstract


Diabetes mellitus (DM) is a chronic disease requires long-term therapy, which can result in high medical costs. This study aims to analyze the cost-effectiveness of oral antidiabetic therapy with pioglitazone compared with glimepiride in type 2 diabetes mellitus outpatients at RSI Siti Hajar Mataram and RSUD H. Moh. Roeslan Kota Mataram from the hospital perspective. This research is an observational method with a cross-sectional design. Data were collected with retrospective and concurrent from medical record and treatment cost data of patients from May-Auguts 2025. Data analysis using the average cost-effectiveness ratio (ACER). The subject of this study is type 2 diabetes mellitus outpatients who met the inclusion and exclusion criteria, with patients received pioglitazone monotherapy and combination is 119 patients, while 133 patients received monotherapy and combination of glimepiride. The result showed that pioglitazone monotherapy could achieve a higher therapeutic target (80,82%) and had lower ACER value Rp 7.867,80 than the glimepiride. While the combination therapy of glimepiride-metformin could achieve a higher therapeutic target (78,57%) and had lower ACER value Rp 5.404,50 than the combination of pioglitazone-metformin. The conclusion of this study pioglitazone monotherapy is perceived to be more cost-effective than glimepiride, while the combination of glimepiride-metformin is perceived to be more cost-effective than combination of pioglitazone-metformin.


Keywords


Type 2 diabetes mellitus; Cost-effectiveness analysis; Pioglitazone; Glimepiride; ACER

Full Text:

PDF

References


American Diabetes Association. (2022). Classification and diagnosis of diabetes : standards of medical care in diabetes — 2022. Diabetes Care, 45(Suppl), 517–538.

Anugrah, C., Purwandari, A., Wirjatmadi, R. B., Mahmudiono, T., Masyarakat, I. K., & Masyarakat, K. (2022). Faktor Risiko Terjadinya Komplikasi Kronis Diabetes Melitus Tipe 2 pada Pra Lansia Risk Factors Chronic Complications of Type 2 Diabetes Mellitus in Pre-Elderly. 6(3), 262–271.

Arsela, K. (2022). Biaya Medik Langsung Pasien Diabetes Melitus Tipe II Rawat Jalan di Rumah Sakit Dr. Soeradji Tirtonegoro Klaten. Journal of Pharmaceutical Science, 19(1), 1–9.

Badan Penelitian dan Pengembangan Kesehatan (Badan Litbangkes). (2018). Laporan Riskesdas 2018 Nasional. Lembaga Penerbit Balitbangkes, p. 674.

Desianti, S., Dan, K., Lestari, K., Raya Bandung, J., Km, S., & Barat, J. (2018). Review Artikel : Kajian Farmakoekonomi Yang Mendasari Pemilihan Pengobatan di Indonesia. Farmaka, 16 (3), 134–145.

Dian, P., Kurnianta, M., Made, P., Ratnasari, D., & Arini, H. D. (2021). Ketercapaian Target Glikemik dan Analisis Faktor-Faktor Terkait Padaa Pasien Diabetes Tipe 2. Original Article MFF, 25(2), 44–50.

Faza, F., Maulina, N., Sugihantoro, H., Muhimmah, I., & Saputra, A. F. (2022). Analisis Efektivitas Biaya Penggunaan Antidiabetik Oral pada Pasien Diabetes Melitus Rawat Jalan di RSU Haji Surabaya. Pharmaceutical Journal of Indonesia, 8(1), 49–58.

Febriana, L., Hazmen, P., & Pangestuti, T. I. (2024). Analisis Efektivitas Biaya Terapi Antidiabetes Oral Kombinasi Pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit X Daerah Wonogiri. Enfermeria Ciencia, 2(1), 13–21.

Islam, Z., Rusdi, K., & Nurhasnah, N. (2017). The Analysis Different of Treatment Diabetes Melitus Type II on General Patients and National Health Insurance Patients (BPJS). Media Farmasi, 14(2), 151–161.

Izza, E. L., Kusnanto, & Yuswanto, T. J. A. (2019). Faktor-Faktor yang Mempengaruhi Perilaku Kepatuhan Diet Penderita DM Suku Jawa. Jurnal Penelitian Kesehatan Forikes, 10 (3), 189–192.

Kim, J. M., Kim, S. S., Kim, J. H., Kim, M. K., Kim, T. N., Lee, S. H., Kim, I. J. (2020). Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy: A randomized, open-label, multicenter, parallel-controlled study. Diabetes and Metabolism Journal, 44(1), 67–77.

Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017). Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open, 7(1), 1–13.

Marzuk, R. H., Oetari, R., & Hanifah, I. R. (2023). Analisis Efektivitas Biaya Terapi Metformin dan Glimepiride Pada Pasien Diabetes Melitus Tipe 2 di RSUD dr. Darsono Pacitan Tahun 2019. Jurnal Ilmu Farmasi Dan Farmasi Klinik (JIFFK), 20(1), 20–27.

Mutmainah, N., Al Ayubi, M., Widagdo, A., Farmasi, F., Muhammadiyah, U., Yani, S. J. A., … Kartasura Surakarta, P. (2020). Kepatuhan dan Kualitas Hidup Pasien Diabetes Melitus Tipe 2 di Rumah Sakit di Jawa Tengah Adherence and Quality of Life Patients of Diabetes Melitus Type 2 in Hospitals in Central Java. Jurnal Farmasi Indonesia, 17(2), 165–173.

Oktavia, S., Budiarti, E., Masra, F., Rahayu, D., & Setiaji, B. (2021). Faktor-Faktor Sosial Demografi Yang Berhubungan Dengan Kejadian Diabetes Melitus Tipe 2. Jurnal Ilmiah Permas, 12(4), 1039–1052.

Perkeni. (2021). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. In PB Perkeni (Perkumpulan Endokrinologi Indonesia) (pp. 1–119).

Pribadi, F. W., Afifah, ., & Widiartini, C. (2021). Cost Analysis Monotherapy of Type 2 Diabetes Mellitus Patients in RSUD. Prof. Dr. Margono Soekarjo. Jenderal Soedirman International Medical Conference, 81–83.

Purnamasari, T. J., Ilone, S., & Setiawan, D. (2023). Cost Utility Analysis Vildagliptin dan Glimepiride dalam Mencegah Komplikasi Mikrovaskuler menggunakan Model Markov. Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 13(4), 266–277.

Rahayu, A., Afdhal, A. F., Hasan, D., Suwarna, F., & Meila, O. (2020). Analisis Efektivitas Biaya Terapi Antihipertensi Kombinasi Tetap Di Satu Rumah Sakit Jakarta Selatan. Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 10(1), 1–13.

Rita, N., Padang, A., Gajah Mada, J., Kesehatan, K., Pangilun, G., & Padang, K. (2018). Hubungan Jenis Kelamin, Olah Raga dan Obesitas Dengan Kejadian Diabetes Melitus Pada Lansia. Jurnal Ilmu Kesehatan (JIK), 2(1), 93–100.

Suharmiati, S., Handayani, L., & Roosihermiatie, B. (2019). Analisis Biaya Obat Unit Rawat Jalan pada Rumah Sakit Badan Layanan Umum (BLU)/ Badan Layanan Umum Daerah (BLUD) di Indonesia. Jurnal Kefarmasian Indonesia, 9(2), 126–139.

Tetuko, A., & Nugraheni, A. (2021). Analisis Efektivitas Biaya Kombinasi Antidiabetik Oral Pada Pasien Rawat Jalan Diabetes Melitus Tipe 2. Cendekia Journal of Pharmcy, 5(2), 105–116.

Tresnawati, N. A., Yusmaini, H., Citrawati, M., & Harfiani, E. (2024). Cost-effectiveness comparison of antidiabetic drugs combination therapy metformin-glimepiride and acarbose-glimepiride Perbandingan efektivitas biaya terapi kombinasi obat antidiabetik metformin-glimepirid dan acarbose-glimepirid. Jurnal Ilmiah Farmasi (Scientific Journal of Pharmacy), 20(1), 118–128.




DOI: https://doi.org/10.31764/lf.v7i1.35915

Refbacks

  • There are currently no refbacks.


EDITORIAL OFFICE: